Syon Capital LLC Trims Position in Eli Lilly and Company (NYSE:LLY)

Syon Capital LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 6.8% in the 4th quarter, Holdings Channel reports. The fund owned 10,499 shares of the company’s stock after selling 763 shares during the period. Eli Lilly and Company makes up about 0.7% of Syon Capital LLC’s investment portfolio, making the stock its 28th biggest position. Syon Capital LLC’s holdings in Eli Lilly and Company were worth $8,105,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. CSM Advisors LLC raised its stake in Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock worth $807,000 after purchasing an additional 245 shares during the period. Oxford Wealth Group LLC raised its holdings in Eli Lilly and Company by 6.4% in the fourth quarter. Oxford Wealth Group LLC now owns 3,636 shares of the company’s stock valued at $2,807,000 after buying an additional 220 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Eli Lilly and Company by 1.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 790,778 shares of the company’s stock valued at $610,481,000 after buying an additional 14,927 shares in the last quarter. MGO One Seven LLC grew its stake in Eli Lilly and Company by 0.3% during the fourth quarter. MGO One Seven LLC now owns 15,709 shares of the company’s stock worth $12,128,000 after buying an additional 54 shares during the period. Finally, Alta Advisers Ltd increased its position in shares of Eli Lilly and Company by 13.9% in the fourth quarter. Alta Advisers Ltd now owns 2,619 shares of the company’s stock worth $2,022,000 after acquiring an additional 319 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $827.87 on Wednesday. The company has a market capitalization of $784.96 billion, a price-to-earnings ratio of 70.70, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a 50-day moving average of $827.10 and a two-hundred day moving average of $818.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on LLY shares. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Citigroup dropped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Morgan Stanley lowered their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a research note on Wednesday, April 9th. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,017.00.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.